Renalytix AI plc (RENX) - Cash Flow Conversion Efficiency

Latest as of December 2024: 4.746x

Based on the latest financial reports, Renalytix AI plc (RENX) has a cash flow conversion efficiency ratio of 4.746x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-6.50 Million ≈ $-790.50 USD) by net assets (GBX-1.37 Million ≈ $-166.57 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RENX equity financing ratio to measure how much of total assets are equity-financed.

Renalytix AI plc - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Renalytix AI plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Renalytix AI plc's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Renalytix AI plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Renalytix AI plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
LANEBURY GROWTH CAP.
F:L01
-0.197x
Kukbo Co. Ltd.
KO:001140
0.946x
Meyer Burger Tech AG
SW:MBTN
-0.961x
Empresaria Group plc
LSE:EMR
0.198x
Prospex Energy PLC
LSE:PXEN
-0.052x
Vergnet
PA:ALVER
0.178x
Braime Group PLC
LSE:BMT
0.088x
Lexington Gold Ltd
LSE:LEX
0.000x

Annual Cash Flow Conversion Efficiency for Renalytix AI plc (2012–2025)

The table below shows the annual cash flow conversion efficiency of Renalytix AI plc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see RENX company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 GBX-7.00 Million
≈ $-851.70
GBX-17.90 Million
≈ $-2.18K
2.557x -33.30%
2024-06-30 GBX-7.85 Million
≈ $-955.60
GBX-30.11 Million
≈ $-3.66K
3.834x +744.54%
2023-12-31 GBX20.76 Billion
≈ $2.53 Million
GBX9.43 Billion
≈ $1.15 Million
0.454x +125.64%
2023-06-30 GBX18.45 Million
≈ $2.25K
GBX-32.67 Million
≈ $-3.98K
-1.771x -67.09%
2022-06-30 GBX43.17 Million
≈ $5.25K
GBX-45.74 Million
≈ $-5.57K
-1.060x -309.13%
2021-06-30 GBX95.10 Million
≈ $11.57K
GBX-24.63 Million
≈ $-3.00K
-0.259x +7.42%
2020-06-30 GBX35.96 Million
≈ $4.38K
GBX-10.06 Million
≈ $-1.22K
-0.280x -97.30%
2019-06-30 GBX28.17 Million
≈ $3.43K
GBX-3.99 Million
≈ $-485.95
-0.142x -100.32%
2018-06-30 GBX-9.39K
≈ $-1.14
GBX-422.00K
≈ $-51.35
44.946x +11298.75%
2016-12-31 GBX17.87 Billion
≈ $2.17 Million
GBX7.05 Billion
≈ $857.42K
0.394x -6.04%
2015-12-31 GBX17.47 Billion
≈ $2.13 Million
GBX7.33 Billion
≈ $891.85K
0.420x +30.71%
2014-12-31 GBX17.26 Billion
≈ $2.10 Million
GBX5.54 Billion
≈ $674.42K
0.321x +4.07%
2013-12-31 GBX20.40 Billion
≈ $2.48 Million
GBX6.29 Billion
≈ $765.80K
0.308x -28.02%
2012-12-31 GBX21.03 Billion
≈ $2.56 Million
GBX9.01 Billion
≈ $1.10 Million
0.429x --

About Renalytix AI plc

LSE:RENX UK Health Information Services
Market Cap
$148.88K
GBX1.22 Billion GBX
Market Cap Rank
#31256 Global
#1051 in UK
Share Price
GBX2.80
Change (1 day)
+5.66%
52-Week Range
GBX1.80 - GBX10.75
All Time High
GBX1220.00
About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more